GlassScriptPhysician profile
Vicente C Trapani
NPI 1710975073
$8,370.73
in general payments reported to CMS, 2019-2025
59 companies · $2,020 in 2025
The $2,020 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $577 · 2021: $1,064 · 2022: $688 · 2023: $1,212 · 2024: $2,352 · 2025: $2,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,379 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,379.46 |
| Education | $204.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,546.88 | 2021-2025 | Ubrelvy, Qulipta |
| Mdd US Operations, LLC | $764.34 | 2019-2025 | Gocovri, Gocovri |
| Pfizer INC. | $545.47 | 2023-2025 | |
| Lilly USA, LLC | $425.62 | 2022-2025 | Amyvid, Kisunla, Emgality |
| Vanda Pharmaceuticals INC. | $374.70 | 2024-2025 | Ponvory |
| Ucb, INC. | $363.50 | 2019-2025 | Briviact, Rystiggo, Bimzelx |
| Eisai INC. | $335.58 | 2020-2025 | |
| Argenx US, INC. | $320.49 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Supernus Pharmaceuticals, INC. | $231.64 | 2019-2025 | Qelbree |
| Alexion Pharmaceuticals, INC. | $227.99 | 2024 | Ultomiris |
| Csl Behring | $215.23 | 2019-2024 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $202.92 | 2020-2025 | Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $169.21 | 2022 | |
| Genzyme Corporation | $158.55 | 2021-2022 | |
| Grifols USA, LLC | $145.51 | 2019-2025 | Xembify, Gamunex-C, Prolastin-C Liquid |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicente Trapani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.